23.63

3.20% -0.78

After Hours: 23.63

4D Molecular Therapeutics Inc (FDMT)

Overview News Price History Option Chain Financials Discussions Forecast

4D Molecular Therapeutics Inc stock is currently priced at $23.63, with a 24-hour trading volume of 359.13K. It has seen a -3.20% decreased in the last 24 hours and a -8.23% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $24.34 pivot point. If it approaches the $22.96 support level, significant changes may occur.

Previous Close:

$24.41

Open:

$24.05

24h Volume:

359.13K

Market Cap:

$1.22B

Revenue:

$20.72M

Net Income/Loss:

$-100.84M

P/E Ratio:

-7.2043

EPS:

-3.28

Net Cash Flow:

$-78.56M

1W Performance:

+4.01%

1M Performance:

-8.23%

6M Performance:

+42.26%

1Y Performance:

+6.97%

1D Range:

$23.50

$24.38

52W Range:

$9.44

$36.25

4D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Name

4D Molecular Therapeutics Inc

Sector

Healthcare (1204)

Industry

Biotechnology (696)

Phone

510-505-2680

Address

5858 Horton Street, Suite 455, EmeryVille

Employee

Twitter

Next Earnings Date

2024-05-21

Latest SEC Filings

FDMT's Discussions on Twitter

4D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-07-24	Resumed	Goldman	Buy
Oct-26-23	Initiated	RBC Capital Mkts	Outperform
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-18-23	Upgrade	Leerink Partners	Market Perform → Outperform
Jul-05-23	Initiated	Chardan Capital Markets	Buy
Jan-30-23	Initiated	BMO Capital Markets	Outperform
Nov-18-22	Initiated	H.C. Wainwright	Buy
Nov-15-22	Upgrade	Goldman	Neutral → Buy
Aug-12-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jun-22-22	Initiated	Jefferies	Buy
Jan-04-22	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	BofA Securities	Buy
Jan-05-21	Initiated	Evercore ISI	Outperform
Jan-05-21	Initiated	Goldman	Neutral

View All

4D Molecular Therapeutics Inc Stock (FDMT) Latest News

4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Lags Revenue Estimates - Yahoo New Zealand News

Yahoo New Zealand News

4D Molecular Therapeutics Inc (FDMT) receives an Overweight rating from Barclays – Knox Daily - Knox Daily

Knox Daily

4D Molecular Therapeutics (NASDAQ:FDMT) Shares Up 3.6% - MarketBeat

MarketBeat

4D Molecular Therapeutics Inc (FDMT) Performance and Fundamentals Dashboard tells a completely different story ... - SETE News

SETE News

Financial Fitness Check: Examining 4D Molecular Therapeutics Inc (FDMT)'s Key Ratios – DWinneX - The Dwinnex

The Dwinnex

4D Molecular Therapeutics Inc (FDMT) produces promising results – US Post News - US Post News

US Post News

4D Molecular Therapeutics Inc Stock (FDMT) Financials Data

4D Molecular Therapeutics Inc (FDMT) Revenue 2024

FDMT reported a revenue (TTM) of $20.72 million for the quarter ending December 31, 2023, a +562.47% rise year-over-year.

4D Molecular Therapeutics Inc (FDMT) Net Income 2024

FDMT net income (TTM) was -$100.84 million for the quarter ending December 31, 2023, a +6.19% increase year-over-year.

4D Molecular Therapeutics Inc (FDMT) Cash Flow 2024

FDMT recorded a free cash flow (TTM) of -$78.56 million for the quarter ending December 31, 2023, a +20.01% increase year-over-year.

4D Molecular Therapeutics Inc (FDMT) Earnings per Share 2024

FDMT earnings per share (TTM) was -$2.66 for the quarter ending December 31, 2023, a +19.88% growth year-over-year.

4D Molecular Therapeutics, Inc. operates as a clinical-stage gene therapy company that develops product candidates using its targeted and evolved adeno-associated viruses vectors. It offers a portfolio of gene therapy product candidates focusing on the ophthalmology, cardiology, and pulmonology therapeutic areas. The company engages in developing 4D-125, which is in a Phase I/II clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase I clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase I/II clinical trial for the treatment of fabry disease. It also focuses on developing two investigational new drug candidates, which include 4D-150 for the treatment of wet age-related macular degeneration; and 4D-710 for the treatment of cystic fibrosis lung disease. The company was founded in 2013 and is headquartered in Emeryville, California.